norfloxacin has been researched along with Bacterial Overgrowth Syndrome in 2 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rao, SSC | 1 |
| Bhagatwala, J | 1 |
| Bustillo, I | 1 |
| Larson, H | 1 |
| Saif, MW | 1 |
1 review available for norfloxacin and Bacterial Overgrowth Syndrome
| Article | Year |
|---|---|
Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.
Topics: Age Factors; Anti-Bacterial Agents; Bacteria; Blind Loop Syndrome; Breath Tests; Clinical Trials as | 2019 |
1 other study available for norfloxacin and Bacterial Overgrowth Syndrome
| Article | Year |
|---|---|
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteria; Blind Loop Syndrome | 2009 |